Cara Therapeutics Inc (STU:69C)
€ 0.2602 -0.006 (-2.25%) Market Cap: 14.50 Mil Enterprise Value: -22.28 Mil PE Ratio: 0 PB Ratio: 22.37 GF Score: 33/100

Cara Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 01:00PM GMT
Release Date Price: €11.08 (+0.91%)
David Amsellem
Piper Sandler - Analyst

Good morning. This is David Amsellem from the Piper Sandler specialty pharma team, day three of the Piper Sandler Healthcare Conference, or I should say 34th Annual Piper Sandler Healthcare Conference. And we're delighted to have Cara Therapeutics with us, Chris Posner, CEO; Joana Goncalves, Chief Medical Officer, did I get your title, right?

I do, okay. And Ryan Maynard, CFO. So thanks everyone for joining us. So lots to talk about given the commercialization of KORSUVA. So I thought we would just dive right in, if that's okay.

Chris Posner
Cara Therapeutics, Inc. - CEO & President

Sure, David.

Questions & Answers

David Amsellem
Piper Sandler - Analyst

So let's just start for those in the audience and on the webcast who may not be as aware of the underlying addressable population. Can you just give us a brief refresher of the underlying population for chronic kidney disease associated pruritus, particularly in the dialysis setting? And how do you see

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot